A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis - Oxfendazole in Fascioliasis Principal Investigators/Program Directors: GARCIA, Hector H./ CABADA, Miguel M. A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis ABSTRACT Fasciola hepatica infection causes human liver disease in wide endemic regions around the world. In the United States, autochthonous cases have been reported in California and Florida, while the Gulf Coast and Northwest states, Hawaii, and Puerto Rico are considered endemic areas. The highest number of human cases in the US occurs among immigrants, refugees, and returning travelers from endemic countries. Chronic infection has been linked to anemia, weight loss, and chronic liver disease. Livestock fascioliasis occurs in 26 states with overlapping areas of autochthonous human transmission in the US. According to the US National Beef Quality Audits, liver condemnation rates increased from 19% in 1991 to 45% in 2022 nationally. Liver condemnation due to fluke infection ranges between 6%-21.7% of all livers. Infected livestock often experience reduced weight gain, milk production, and fecundity further contributing to the often-unaccounted economic burden. Triclabendazole (TCBZ) is the only effective drug to treat human fascioliasis. However, it is not widely available and recently reports about resistance in livestock and decreased efficacy in humans raise concerns for the availability of effective treatment in human infections. TCBZ resistance in human has been reported in The Netherlands, Turkey, Chile, Portugal, and Peru. Oxfendazole (OXF) is a veterinary benzimidazole with a wide anti-helminthic spectrum, highly efficacious against Taenia solium cysticercosis and other helminths. We have completed animal toxicology and phase 1 OXF studies in humans, confirming the high bioavailability of OXF and, importantly, its safety. These data strongly suggest that OXF is an excellent candidate for the treatment of human fascioliasis. Therefore, we propose to compare two oral OXF treatment regimens, a single 20 mg/kg dose and two 20 mg/kg doses, against the standard of care of two 10 mg/kg oral doses of TCBZ for the treatment of 336 children and adults with chronic Fasciola hepatica infection in endemic areas of Cusco, Peru. In addition, population PK modeling will be performed among subjects randomized to the OXF arms. This study will evaluate the efficacy, safety, and population pharmacokinetics of OXF. This application builds upon our 25-years of experience working with OXF and takes advantage of the solid expertise of the PIs in helminth infections, prior pivotal randomized clinical trials of anti-parasitic treatment in cysticercosis, and our continued work in a well-known Fasciola-endemic region in the Andes Mountains of Cusco. This trial has the potential to provide a new standard of care for the treatment of chronic fascioliasis It will provide additional pharmacokinetic and safety data to advance OXF development as a human drug. New effective treatment is urgently needed in endemic countries and in countries with large immigrant and short-term traveler populations at risk of getting the infection such as the United States.